Latest News Ampio Announces Investor Call on its Aytu BioScience Common Stock Distribution on Thursday, November 19, 4:15 p.m. ESTDate: November 18, 2015 | READ MORE > Ampio Will Distribute Aytu BioSciences Stock to Ampio Shareholders of Record on December 1, 2015Date: November 17, 2015 | READ MORE > Ampio Intends to Distribute Aytu BioScience Stock to Ampio ShareholdersDate: November 2, 2015 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Updates On the Regulatory Path for FDA Approval of Optina™, an Oral Treatment for Diabetic Macular Edema (DME)Date: October 14, 2015 | READ MORE > AMPIO Receives Special Protocol Assessment (SPA) from the FDA and Commences Second Phase III pivotal trial of Ampion™Date: September 22, 2015 | READ MORE > Clinical Trial Design – AP-003-B (PIVOT) Study SynopsisDate: September 22, 2015 | READ MORE > Ampio Hosts Investor Call to Discuss Updates on Ampion™ and Optina™ (Audio Available)Date: July 17, 2015 | READ MORE > Ampio Announces Investor Call on Thursday, July 16, 4:30 p.m. EDTDate: July 9, 2015 | READ MORE > Ampio Pharmaceuticals Announces Additional Statistically Significant Study Results for Optina™ in the Treatment of Diabetic Macular Edema (DME)Date: June 22, 2015 | READ MORE > Ampio Pharmaceuticals Provides Information on the Formation and Significance of Aytu BioScience to Ampio ShareholdersDate: June 16, 2015 | READ MORE > Ampio Pharmaceuticals Reports the Synergistic Effects of Ampion in the Treatment of Osteoarthritis of the Knee in Three Peer-reviewed PublicationsDate: June 9, 2015 | READ MORE > Ampio Pharmaceuticals Announces Update of STRIDE Study for the Investigation of Pain Associated with OsteoarthritisDate: June 4, 2015 | READ MORE > Ampio Pharmaceuticals Announces Positive Study Results on Optina for the Treatment of Diabetic Macular EdemaDate: May 21, 2015 | READ MORE > Ampio Announces Top-Line Results of the Double-Blind Multiple Intra-Articular Injections (STRUT) Study of Ampion™ in Patients with Moderate to Severe Osteoarthritis of the KneeDate: February 25, 2015 | READ MORE > Ampio Updates Status of Clinical Trials and Manufacturing FacilityDate: November 12, 2014 | READ MORE > Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facilityDate: July 30, 2014 | READ MORE > Ampio Receives FDA Confirmation that The Spring Study is Pivotal and Will Initiate the Final Pivotal Trial for Ampion™ Biological License Application (BLA)Date: December 2, 2013 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical TrialDate: August 14, 2013 | READ MORE >
